Brief: Paratek Pharmaceuticals Receives $36.4 Mln Milestone Payment Associated With Nuzyra
05/01/2023 14:00
Jan 5 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK PHARMACEUTICALS RECEIVES $36.4 MILLION MILESTONE
PAYMENT
ASSOCIATED WITH THE SECOND PROCUREMENT OF NUZYRA® (OMADACYCLINE)
UNDER BARDA PROJECT BIOSHIELD CONTRACT
* PARATEK PHARMACEUTICALS RECEIVES $36.4 MILLION MILESTONE
PAYMENT
ASSOCIATED WITH THE SECOND PROCUREMENT OF NUZYRA® (OMADACYCLINE)
UNDER BARDA PROJECT BIOSHIELD CONTRACT
Source text for Eikon: ID:nGNX3fYN3L
Further company coverage: PRTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million